<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770337</url>
  </required_header>
  <id_info>
    <org_study_id>NE001</org_study_id>
    <nct_id>NCT04770337</nct_id>
  </id_info>
  <brief_title>Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy</brief_title>
  <official_title>STARSTIM: SAFETY AND THERAPEUTIC MEASURES OF TRANSCRANIAL CATHODAL DIRECT CURRENT STIMULATION (TDCS) IN PATIENTS WITH REFRACTORY FOCAL EPILEPSY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroelectrics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuroelectrics Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multiple site, randomized, double blinded parallel-group controlled study. The&#xD;
      purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily&#xD;
      sessions with the STARSTIM device, which delivers transcranial cathodal direct current&#xD;
      stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions&#xD;
      over a 2-week period. The subjects will be followed for an additional 10 weeks post&#xD;
      treatment. Quality of Life questionnaires and adverse events will be collected and evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design is an evaluation of the STARSTIM device (tDCS) in subjects over 9 years of age,&#xD;
      diagnosed with epilepsy with focal seizures with or without focal to bilateral tonic clonic&#xD;
      seizures. Seizure diaries will be collected for 12 weeks to establish a rate of seizure for&#xD;
      each subject prior to treatment. Subjects will be randomized in a 1:1 ratio to receive an&#xD;
      active STARSTIM treatment or a sham treatment. Neither the study investigator nor subject&#xD;
      shall be notified of the treatment assignment. Treatment will be done daily at the&#xD;
      investigator's site for 10 days. A Seizure Diary will be maintained through the course of the&#xD;
      treatment and the follow up period. Subjects will have 3 follow up visits to evaluate their&#xD;
      seizure rate, adverse events, medications and quality of life. A Data Safety Monitoring Board&#xD;
      will be utilized to evaluate safety events through study milestones. Seizure frequency rates&#xD;
      pre, during and post treatment will be evaluated for both the active and sham treatment arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multiple site, randomized, double blinded parallel-group controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment. Neither the study investigator nor subject shall be notified of the treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in seizure frequency from 12-week baseline to the 12 weeks post-randomization, which includes the two-week active intervention</measure>
    <time_frame>From 12-week baseline to the 12 weeks post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of treatment 'response' within the six weeks following initiative of intervention (i.e. between baseline and visit 12), where responders are those subjects with at least 50% reduction in seizure rate</measure>
    <time_frame>Within the six weeks following initiative of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STARSTIM device treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STARSTIM device</intervention_name>
    <description>Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.</description>
    <arm_group_label>STARSTIM device treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Device</intervention_name>
    <description>Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp</description>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 9 years old or older&#xD;
&#xD;
          2. Diagnosis of epilepsy with focal seizures with or without focal to bilateral tonic&#xD;
             clonic seizures (International League Against Epilepsy classification). Diagnosis&#xD;
             established by both clinical history and an EEG consistent with focal seizures.&#xD;
&#xD;
          3. Epilepsy is refractory to treatment, defined as: failure to achieve adequate seizure&#xD;
             control despite demonstrated compliance, according to medical records, on at least two&#xD;
             (2) FDA-approved ASDs at a daily dose considered therapeutic for the patient's&#xD;
             demographic according to package labeling, within approximately the last 3 years.&#xD;
&#xD;
          4. Seizure frequency &gt;= 3 and &lt;= 20 per month, over the past year.&#xD;
&#xD;
          5. Currently on 1-4 ASDs with no changes in antiepileptic drug doses in the 3 weeks prior&#xD;
             to enrollment in the study and no planned dose changes during the trial. Changes after&#xD;
             enrollment are permitted only if clinically necessary.&#xD;
&#xD;
          6. An MRI scan of the brain using 1.5 Tesla magnet, or greater, with T1, T2, and FLAIR&#xD;
             sequences, performed within past 3 years and more recently than any craniotomy or&#xD;
             skull burr hole procedure.&#xD;
&#xD;
          7. Seizure focus that allows design of an appropriate stimulation montage&#xD;
&#xD;
          8. Available seizure history and supporting data&#xD;
&#xD;
          9. All female study subjects of child-bearing age are required to have a pregnancy test.&#xD;
&#xD;
             Additionally, all females of childbearing potential will be required to use an&#xD;
             effective method of birth control (defined as having a documented failure rate of&#xD;
             &lt;=1%; for women using enzyme-inducing ASDs hormonal contraceptives will not be&#xD;
             considered as effective).&#xD;
&#xD;
         10. Written informed consent obtained from study subject or subject's legal representative&#xD;
             and ability for study subject to comply with the requirements of the study.&#xD;
&#xD;
         11. Assent from pediatric subjects when appropriate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the subject or the integrity of the data.&#xD;
&#xD;
          2. Evidence for more than one seizure focus. (NOTE: For this study, a seizure focus is&#xD;
             defined as a cortical region confined to one hemisphere and either one lobe or on a&#xD;
             junction of two adjacent lobes from which seizures arise, as documented by scalp or&#xD;
             intracranial EEG, that is either supported or not refuted by MRI, and either supported&#xD;
             or not refuted by clinical semiology).&#xD;
&#xD;
          3. Seizure focus is one of: interhemispheric, cingulate, or orbitofrontal&#xD;
&#xD;
          4. Seizure focus is hemispheric or poorly defined&#xD;
&#xD;
          5. History of psychogenic nonepileptic seizures, or physiologic nonepileptic seizures and&#xD;
             Non-epileptogenic events, including suspicion for or a significant history of syncope&#xD;
&#xD;
          6. Seizures of generalized onset&#xD;
&#xD;
          7. Status epilepticus in the last 12 months&#xD;
&#xD;
          8. Presence of any disease, medical condition or physical condition that, in the opinion&#xD;
             of the Investigator, may compromise interfere, limit, effect or reduce the subject's&#xD;
             ability to complete a study of 24 weeks duration&#xD;
&#xD;
          9. Presence of any disease, medical condition or physical condition that, in the opinion&#xD;
             of the Investigator, may adversely impact the safety of the subject or the integrity&#xD;
             of the data.&#xD;
&#xD;
         10. Damaged skin on scalp that may interfere with tDCS stimulation.&#xD;
&#xD;
         11. Pregnant or unwilling to practice birth control during participation in the study.&#xD;
&#xD;
         12. Nursing mothers.&#xD;
&#xD;
         13. Any cranial metal implants (excluding â‰¦1 mm thick epicranial titanium skull plates and&#xD;
             dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator,&#xD;
             medication infusion pump, cochlear implant, vagus nerve stimulator).&#xD;
&#xD;
         14. Previous surgeries opening the skull leaving skull defects capable of allowing the&#xD;
             insertion of a cylinder with a radius greater or equal to 5 mm.&#xD;
&#xD;
         15. A history of addiction to, dependence on, abuse of, misuse of, distribution of, or use&#xD;
             of any illicit substance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abou-Khalil Bassel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abou-Khalil Bassel</last_name>
      <phone>615-875-2532</phone>
      <email>bassel.abou-khalil@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Osborn</last_name>
      <email>melissa.osborn@vumc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

